The Next Nuclear Super-Stock? ️ Why ASPI Could 10x (Or Go to Zero)

Is ASP Isotopes (Ticker: ASPI) the holy grail of deep tech or
just a Wall Street science experiment? ️


In this episode of Rendite Radar, we dismantle the hype
surrounding one of the most volatile stocks on the market. From
curing cancer to powering the next generation of Nuclear Reactors
(SMRs), ASPI promises to change the world. But a look at the
financials tells a different story: $96M net loss, massive
dilution, and revenue coming from... construction projects? ️





We dive deep into:


The Numbers: Breaking down the "fake" 500% revenue growth.


The Tech: Why HALEU and Medical Isotopes are the "new gold."


The Risks: Cash burn, regulatory nightmares, and the Russia
connection.


The Verdict: Is this a buy for 2026 or a trap?


Timestamps: 0:00 - Intro: Sci-Fi or Scam? 1:15 - The Revenue
"Trick" Explained 3:30 - The 96 Million Dollar Loss (It's
complicated) 5:45 - The Bull Case: Nuclear, Quantum & Helium
8:20 - The Bear Case: Dilution & Execution Risk 10:50 - Final
Verdict


#ASPI #NuclearEnergy #StockAnalysis #Investing #Uranium #SMR
#RenditeRadar





SOCIAL MEDIA:


Spotify: https://shorturl.at/HXtGR


Instagram: https://shorturl.at/UDsjw


Tiktok: https://shorturl.at/9oLNJ


Disclaimer: This podcast does not constitute investment advice.
All content is for informational purposes only. Do your own due
diligence.